Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure

被引:83
作者
Mellin, V
Isabelle, M
Oudot, A
Vergely-Vandriesse, C
Monteil, C
Di Meglio, B
Henry, JP
Dautreaux, B
Rochette, L
Thuillez, C
Mulder, P
机构
[1] Fac Med & Pharm, INSERM, U644, F-76183 Rouen, France
[2] Lab Physiopathol & Pharmacol Cardiovasc Expt, Dijon, France
关键词
heart failure; allopurinol; reactive oxygen species;
D O I
10.1093/eurheartj/ehi305
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Oxidative stress, i.e. imbalance between reactive oxygen species (ROS) and antioxidant defences, contributes to the progression of chronic heart failure (CHF). Acute inhibition of xanthine oxidase (XO), which produces ROS, improves mechanical efficiency of the failing heart, but whether long-term XO inhibition exerts beneficial effects in CHF is unknown. Methods and results In rats with established CHF induced by left coronary ligation, we assessed the effects of a 5-day and a 10-week treatment with the XO inhibitor allopurinol (50 mg kg(-1) day(-1)) on haemodynamics and left ventricular (LV) function and structure. Both acute and chronic allopurinol treatment increase cardiac output without modification of arterial pressure, but only chronic allopurinol treatment reduces LV end-diastolic pressure and LV relaxation constant. Chronic allopurinol treatment decreases both LV systolic and diastolic diameters, but acute allopurinol treatment only decreases W systolic diameter. Moreover, chronic allopurinol decreases LV weight and collagen density. Despite XO inhibition after acute and chronic allopurinol treatment, as both treatments reduce uric acid plasma levels, only acute allopurinol treatment reduces LV ROS determined using electron spin resonance spectroscopy. However, the CHF-enhanced myocardial thiobarbituric acid reactive substances levels were never modified. Conclusion In experimental CHF, long-term allopurinol treatment, initiated in a pathological state of overt CHF, improves W haemodynamics and function and prevents W remodelling. These long-term effects are, at least partially, caused by a transient reduction of myocardial ROS shortly after initiation of allopurinol treatment, but whether other mechanism(s), independent of myocardial redox 'status', such as reduced inflammation, are implicated remains to be confirmed.
引用
收藏
页码:1544 / 1550
页数:7
相关论文
共 37 条
[1]   Protective effect of antioxidants on pulmonary endothelial function after cardiopulmonary bypass [J].
Angdin, M ;
Settergren, G ;
Starkopf, J ;
Zilmer, M ;
Zilmer, K ;
Vaage, J .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2003, 17 (03) :314-320
[2]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[3]   Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy [J].
Cappola, TP ;
Kass, DA ;
Nelson, GS ;
Berger, RD ;
Rosas, GO ;
Kobeissi, ZA ;
Marbán, E ;
Hare, JM .
CIRCULATION, 2001, 104 (20) :2407-2411
[4]   Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy [J].
Cicoira, M ;
Zanolla, L ;
Rossi, A ;
Golia, G ;
Franceschini, L ;
Brighetti, G ;
Zeni, P ;
Zardini, P .
AMERICAN HEART JOURNAL, 2002, 143 (06) :1107-1111
[5]  
Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
[6]   URATE CRYSTALS STIMULATE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA FROM HUMAN BLOOD MONOCYTES AND SYNOVIAL-CELLS - CYTOKINE MESSENGER-RNA AND PROTEIN KINETICS, AND CELLULAR-DISTRIBUTION [J].
DIGIOVINE, FS ;
MALAWISTA, SE ;
THORNTON, E ;
DUFF, GW .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) :1375-1381
[7]   Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure - Results from 2 placebo-controlled studies [J].
Doehner, W ;
Schoene, N ;
Rauchhaus, M ;
Leyva-Leon, F ;
Pavitt, DV ;
Reaveley, DA ;
Schuler, G ;
Coats, AJS ;
Anker, SD ;
Hambrecht, R .
CIRCULATION, 2002, 105 (22) :2619-2624
[8]   Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure [J].
Ekelund, UEG ;
Harrison, RW ;
Shokek, O ;
Thakkar, RN ;
Tunin, RS ;
Senzaki, H ;
Kass, DA ;
Marbán, E ;
Hare, JM .
CIRCULATION RESEARCH, 1999, 85 (05) :437-445
[9]   Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction -: A new action for an old drug? [J].
Engberding, N ;
Spiekermann, S ;
Schaefer, A ;
Heineke, A ;
Wiencke, A ;
Müller, M ;
Fuchs, M ;
Hilfiker-Kleiner, D ;
Hornig, B ;
Drexler, H ;
Landmesser, U .
CIRCULATION, 2004, 110 (15) :2175-2179
[10]   Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure [J].
Freudenberger, RS ;
Schwarz, RP ;
Brown, J ;
Moore, A ;
Mann, D ;
Givertz, MM ;
Colucci, WS ;
Hare, JM .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) :1509-1516